UNSPSC 51171932: Cinitapride

This classification denotes a serotonin antagonist and serotonin agonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier R8I97I2L24. European Medicines Agency schedules Cinitapride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06298MIG. Cinitapride generally arises in the molecular formula C21H30N4O4.

UNSPSC 51171932 Cinitapride, a Commodity code, names a single active pharmaceutical ingredient but maps poorly to the recent state and local opportunities actually posted under this code. The three opportunities listed—offender drug testing services in Texas, a direct-to-manufacturer pharmacy program inquiry from Texas HHS, and a multistate generic pharmaceuticals cooperative purchasing agreement led by Minnesota—reflect broader pharmaceutical procurement and testing services rather than the specific drug product the code nominally identifies. State and local governments soliciting under this code are acquiring either specimen-collection and drug-screening services (Collin County), pharmacy benefit program design and direct-manufacturer contracting capability (Texas HHS Commission), or access to generic and over-the-counter pharmaceutical products through cooperative purchasing channels (Minnesota Multistate Cooperative Purchasing Alliance serving state and local facilities across multiple states including Oregon). Issuing bodies include county-level community supervision departments, state health and human services agencies, and regional cooperative purchasing organizations administered by state procurement offices.

The most recent activity concentrates in Texas and Minnesota. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026, due July 23, 2026, for offender specimen collection and drug testing services across two sites in Plano and McKinney with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026, with three optional one-year renewals. Texas Health and Human Services Commission issued RFI No. HHS0017013 in late March 2026 to gather vendor capabilities on direct-to-manufacturer prescription contracting before developing a formal procurement strategy. The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), posted a Request for Proposal on January 20, 2026, due March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers with a July 1, 2026 effective date for awarded vendors.